PT - JOURNAL ARTICLE AU - Zhaozhi Qian AU - Ahmed M. Alaa AU - Mihaela van der Schaar AU - Ari Ercole TI - Between-centre differences for COVID-19 ICU mortality from early data in England AID - 10.1101/2020.04.19.20070722 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.19.20070722 4099 - http://medrxiv.org/content/early/2020/05/15/2020.04.19.20070722.short 4100 - http://medrxiv.org/content/early/2020/05/15/2020.04.19.20070722.full AB - The high numbers of COVID-19 patients developing severe respiratory failure has placed exceptional demands on ICU capacity around the world. Understanding the determinants of ICU mortality is important for surge planning and shared decision making. We used early data from the COVID-19 Hospitalisation in England Surveillance System (from the start of data collection 8th February -14th April 2020) to look for factors associated with ICU outcome in the hope that information from such timely analysis may be actionable before the outbreak peak. Immunosuppression, chronic heart/renal disease and age were key determinants of ICU mortality in a proportional hazards mixed effects model. However variation in site-stratified random effects were even comparable in magniture suggesting substantial between-centre variability in mortality. Notwithstanding possible ascertainment and lead-time effects, these early results motivate comparative effectiveness research to understand the origin of such differences and optimise surge ICU provision.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot externally fundedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data controlled by Public Health England. Under the terms of our data sharing agreement, the authors are not able to re-share the source data but will entertain re-quests for scientific collaboration.